Phaseline

Companies › ScandiBio Therapeutics

ScandiBio Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CMA2
Combined metabolic activator containing N-acetyl-L-cysteine, L-carnitine-L-tartrate, nicot
NAC, LCAT, NICOTINAMIDE, L-SERINEPhase 3Alzheimer Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07062198CMA2Phase 3Alzheimer DiseaseNeurologySep 2026

Targets

NAC (1) LCAT (1) NICOTINAMIDE (1) L-SERINE (1)

Companies with the same targets

–

Companies built like this

Prilenia Ambros Therapeutics Cerevance Green Valley (Shanghai) Pharmaceuticals CereMark Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.